Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838–861 (2024).
Google Scholar
Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489–500 (2024).
Google Scholar
Pulendran, B., Arunachalam, P. S. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
Google Scholar
Zhao, T. M. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023).
Google Scholar
Xie, C. Y., Yao, R. H. & Xia, X. J. The advances of adjuvants in mRNA vaccines. npj Vaccines 8, 162 (2023).
Google Scholar
Wang, X. STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature 641, 202–210 (2025).
Google Scholar
Yin, Q. et al. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nat. Mater. 22, 380–390 (2023).
Google Scholar
Uslu, U. et al. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. Nat. Commun. 15, 3933 (2024).
Google Scholar
Yum, S., Li, M. H., Fang, Y. & Chen, Z. J. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. Proc. Natl Acad Sci. USA 118, e2100225118 (2021).
Google Scholar
Chen, X. A. et al. Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity. Nat. Commun. 14, 4584 (2023).
Google Scholar
Liu, X. et al. ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade. Nat. Commun. 14, 4066 (2023).
Google Scholar
Dosta, P. et al. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat. Nanotechnol. 18, 1351–1363 (2023).
Google Scholar
Lu, X. G. et al. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. Sci. Transl. Med. 12, eaaz6606 (2020).
Google Scholar
Li, S. et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat. Biomed. Eng 5, 455–466 (2021).
Google Scholar
Wang, J. et al. STING licensing of type I dendritic cells potentiates antitumor immunity. Sci. Immunol. 9, eadj3945 (2024).
Google Scholar
Wang, B. et al. Delivery of mRNA encoding interleukin-12 and a stimulator of interferon genes agonist potentiates antitumor efficacy through reversing T cell exhaustion. ACS Nano 18, 15499–15516 (2024).
Google Scholar
Jneid, B. et al. Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci. Immunol. 8, eabn6612 (2023).
Google Scholar
Wu, Y. X. et al. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function. Cell Mol. Immunol. 18, 632–643 (2021).
Google Scholar
Geng, F. H. et al. Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response. Cell Mol. Immunol. 21, 856–872 (2024).
Google Scholar
Luo, W. W. et al. Transcription-independent regulation of STING activation and innate immune responses by IRF8 in monocytes. Nat. Commun. 13, 4822 (2022).
Google Scholar
Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373–380 (2022).
Google Scholar
Zhang, D. et al. A non-canonical cGAS–STING–PERK pathway facilitates the translational program critical for senescence and organ fibrosis. Nat. Cell Biol. 24, 766–782 (2022).
Google Scholar
Franz, K. M., Neidermyer, W. J., Tan, Y.-J., Whelan, S. P. J. & Kagan, J. C. STING-dependent translation inhibition restricts RNA virus replication. Proc. Natl Acad. Sci. USA 115, E2058–E2067 (2018).
Google Scholar
Liu, D. et al. STING directly activates autophagy to tune the innate immune response. Cell Death Differ. 26, 1735–1749 (2018).
Google Scholar
Hao, Y. Y. et al. Tumor-selective activation of Toll-like receptor 7/8 agonist nano-immunomodulator generates safe anti-tumor immune responses upon systemic administration. Angew. Chem. Int. Ed. Engl. 61, e202214992 (2022).
Google Scholar
Wang, R. N. et al. Spatiotemporal nano-regulator unleashes anti-tumor immunity by overcoming dendritic cell tolerance and T cell exhaustion in tumor-draining lymph nodes. Adv. Mater. 37, e2412141 (2025).
Google Scholar
Zhang, M. et al. STING-activating polymers boost lymphatic delivery of mRNA vaccine to potentiate cancer immunotherapy. Adv. Mater. 37, 2412654 (2024).
Google Scholar
Han, X. X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105–1114 (2023).
Google Scholar
Zhang, Y. et al. STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2. Nano Lett. 23, 2593–2600 (2023).
Google Scholar
Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).
Google Scholar
Tse, S.-W. et al. mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response. Mol. Ther. 29, 2227–2238 (2021).
Google Scholar
Tang, C. H. A. et al. STING regulates BCR signaling in normal and malignant B cells. Cell. Mol. Immunol. 18, 1016–1031 (2021).
Google Scholar
Liu, W. et al. Selective reactivation of STING signaling to target Merkel cell carcinoma. Proc. Natl Acad. Sci. USA 117, 13730–13739 (2020).
Google Scholar
Patel, N. et al. Development and characterization of an in vitro cell-based assay to predict potency of mRNA-LNP-based vaccines. Vaccines (Basel) 11, 1224 (2023).
Google Scholar
Huysmans, H. et al. Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin. Mol. Ther. Nucleic Acids 17, 867–878 (2019).
Google Scholar
Zevini, A., Olagnier, D. & Hiscottt, J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 38, 194–205 (2017).
Google Scholar
Huang, T. Z., Sun, C. L., Du, F. H. & Chen, Z. J. J. STING-induced noncanonical autophagy regulates endolysosomal homeostasis. Proc. Natl Acad. Sci. USA 122, e2415422122 (2025).
Google Scholar
Keller, M. D., Torres, V. J. & Cadwell, K. Autophagy and microbial pathogenesis. Cell Death Differ. 27, 872–886 (2020).
Google Scholar
Whitmarsh-Everiss, T. & Laraia, L. Small molecule probes for targeting autophagy. Nat. Chem. Biol. 17, 653–664 (2021).
Google Scholar
Krishnamoorthy, J. et al. Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells. Cell Death Dis. 9, 254 (2018).
Google Scholar
Chang, J., Hou, S., Yan, X., Li, W. & Xiao, J. Discovery of novel STING inhibitors based on the structure of the mouse STING agonist DMXAA. Molecules 28, 2906 (2023).
Google Scholar
Pan, B. S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020).
Google Scholar
Gui, X. et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature 567, 262–266 (2019).
Google Scholar
Malli Cetinbas, N. et al. Tumor cell-directed STING agonist antibody–drug conjugates induce type III interferons and anti-tumor innate immune responses. Nat. Commun. 15, 5842 (2024).
Google Scholar
Wang, Y. et al. Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways. Nat. Nanotechnol. 19, 856–866 (2024).
Google Scholar
Lynn, G. M. et al. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat. Biotechnol. 38, 320–332 (2020).
Google Scholar
Xia, T. L., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14, 282–297 (2016).
Google Scholar
Wang, J. et al. A dual-STING-activating nanosystem expands cancer immunotherapeutic temporal window. Cell Rep. Med. 5, 101797 (2024).
Google Scholar
Zhang, G., Tang, T. Y., Chen, Y. F., Huang, X. & Liang, T. B. mRNA vaccines in disease prevention and treatment. Signal Transduct. Target. Ther. 8, 365 (2023).
Google Scholar
Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).
Google Scholar
Monroe, J. et al. N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation. Nat. Commun. 15, 8119 (2024).
Google Scholar
Benoit-Lizon, I. et al. CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of Th1 and Th9 cells. J. Immunother. Cancer 10, e003459 (2022).
Google Scholar
Aval, L. M., Pease, J. E., Sharma, R. & Pinato, D. J. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J. Clin. Med. 9, 3323 (2020).
Google Scholar
Meares, G. P. et al. PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation. Mol. Cell. Biol. 34, 3911–3925 (2023).
Google Scholar
Gehrcken, L., Deben, C., Smits, E. & van Audenaerde, J. R. M. STING agonists and how to reach their full potential in cancer immunotherapy. Adv. Sci. (Weinh.) 12, e2500296 (2025).
Google Scholar
Han, C. H. et al. Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nat. Immunol. 21, 1470 (2020).
Google Scholar
Han, C. et al. Polysome profiling followed by quantitative PCR for identifying potential micropeptide encoding long non-coding RNAs in suspension cell lines. STAR Protoc. 3, 101037 (2022).
Google Scholar
Zhao, Z. et al. Boosting RNA nanotherapeutics with V-ATPase activating non-inflammatory lipid nanoparticles to treat chronic lung injury. Nat. Commun. 16, 6477 (2025).
Google Scholar
